pre_text: alexion pharmaceuticals , inc . notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases ( including facilities and equipment ) as of december 31 , 2007 are: .
post_text: 9 . commitments and contingencies legal proceedings on march 16 , 2007 , pdl biopharma , inc. , or pdl , filed a civil action against alexion in the u.s . district court for the district of delaware . pdl claims willful infringement by alexion of pdl patents due to sales of soliris . pdl seeks unspecified damages , but no less than a reasonable royalty , plus attorney 2019s fees . alexion has denied pdl's claims . in addition , we filed counterclaims seeking declarations of non-infringement and invalidity of certain u.s . patents held by pdl . alexion believes it has good and valid defenses to pdl's claims and intends to vigorously defend the case and pursue its counterclaims . on february 4 , 2008 , sb2 , inc . filed a civil action against alexion in the united states district court for the northern district of california . sb2 , inc . claims willfull infringement by alexion of sb2 , inc . patents due to sales of soliris . sb2 , inc . seeks unspecified monetary damages , equitable relief and attorneys fees . alexion believes it has good and valid defenses to sb2's claims and intends to vigorously defend the case and pursue its counterclaims . the results of such civil actions cannot be predicted with certainty due to their early stages . however , depending on the outcome of these legal matters , the operating results of the company could be materially impacted through adjustments to cost of sales ( see notes 2 , 6 and 15 for additional information related to royalties ) . product supply the large-scale product supply agreement dated december 18 , 2002 , or the lonza agreement , between lonza sales ag , or lonza , and us , relating to the manufacture of soliris , was amended in june 2007 . we amended our supply agreement to provide for additional purchase commitments of soliris of $ 30000 to $ 35000 through 2013 . such commitments may only be cancelled in limited circumstances. .
table: 2008 $4,935
table: 2009 3,144
table: 2010 3,160
table: 2011 3,200
table: 2012 2,768
table: Thereafter 9,934
question: Analyse this data from a financial earnings document. what is the average future minimum annual rental payment for the next five years?